WallStreetZenWallStreetZen

NASDAQ: AKRO
Akero Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for AKRO

Based on 3 analysts offering 12 month price targets for Akero Therapeutics Inc.
Min Forecast
$30.00+48.08%
Avg Forecast
$40.67+100.73%
Max Forecast
$50.00+146.79%

Should I buy or sell AKRO stock?

Based on 3 analysts offering ratings for Akero Therapeutics Inc.
Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their AKRO stock forecasts and price targets.

AKRO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-22
lockedlocked$00.00+00.00%2024-03-05
lockedlocked$00.00+00.00%2024-03-05

1 of 1

Forecast return on equity

Is AKRO forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.42%

Forecast return on assets

Is AKRO forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

AKRO revenue forecast

What is AKRO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$45.9M
Avg 2 year Forecast
$116.1M
Avg 3 year Forecast
$371.2M

AKRO vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
AKRO$20.26$40.67+100.73%Buy
ABCL$3.90$11.50+194.87%Strong Buy
MNKD$4.19$7.00+67.06%Strong Buy
MIRM$24.02$52.75+119.61%Strong Buy
TARS$32.76$48.00+46.52%Buy

Akero Therapeutics Stock Forecast FAQ

Is Akero Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AKRO) stock is to Buy AKRO stock.

Out of 3 analysts, 1 (33.33%) are recommending AKRO as a Strong Buy, 1 (33.33%) are recommending AKRO as a Buy, 1 (33.33%) are recommending AKRO as a Hold, 0 (0%) are recommending AKRO as a Sell, and 0 (0%) are recommending AKRO as a Strong Sell.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.

What is AKRO's revenue growth forecast for 2026-2028?

(NASDAQ: AKRO) Akero Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.08%.

Akero Therapeutics's revenue in 2024 is $0.On average, 3 Wall Street analysts forecast AKRO's revenue for 2026 to be $2,586,364,734, with the lowest AKRO revenue forecast at $1,453,039,198, and the highest AKRO revenue forecast at $3,644,364,178. On average, 1 Wall Street analysts forecast AKRO's revenue for 2027 to be $6,533,328,124, with the lowest AKRO revenue forecast at $6,533,328,124, and the highest AKRO revenue forecast at $6,533,328,124.

In 2028, AKRO is forecast to generate $20,897,079,418 in revenue, with the lowest revenue forecast at $20,897,079,418 and the highest revenue forecast at $20,897,079,418.

What is AKRO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: AKRO) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is AKRO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AKRO price target, the average AKRO price target is $40.67, with the highest AKRO stock price forecast at $50.00 and the lowest AKRO stock price forecast at $30.00.

On average, Wall Street analysts predict that Akero Therapeutics's share price could reach $40.67 by Apr 22, 2025. The average Akero Therapeutics stock price prediction forecasts a potential upside of 100.73% from the current AKRO share price of $20.26.

What is AKRO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: AKRO) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.